Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly EBT Margin of 34156.41% for Q1 2026, down 3232086.0% year-over-year from N/an in Q1 2025, and down 312.02% quarter-over-quarter from 8289.97% in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) EBT Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported EBT Margin for 12 consecutive years, with 34156.41% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 3232086.0% year-over-year to 34156.41%; the TTM figure through Mar 2026 stood at 16277.07% (down 1599731.0% YoY), while the FY2025 annual figure was 4987.31%, down 478577.0% from the prior year.
- EBT Margin fell to 34156.41% in Q1 2026 per RNAC's latest filing, from 8289.97% in the prior quarter.
- Across five years, EBT Margin topped out at 3024.88% in Q4 2024 and bottomed at 34156.41% in Q1 2026.
- Historically, EBT Margin has averaged 3204.46% across 5 years, with a median of 230.19% in 2023.
- Annual changes were most pronounced in 2024 — EBT Margin jumped 540400 bps — and 2026, when it tumbled 3232086 bps.
- Cartesian Therapeutics' EBT Margin stood at 33.37% in 2022, then plunged by 7229 bps to 2379.12% in 2023, then surged by 227 bps to 3024.88% in 2024, then slumped by 374 bps to 8289.97% in 2025, then sank by 312 bps to 34156.41% in 2026.
- Business Quant data shows RNAC's EBT Margin at 34156.41% in Q1 2026, 8289.97% in Q4 2025, and 1835.55% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Cartesian Therapeutics | 271.98 Mn | 271.98 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -32,657.69% |
| Dec 31, 2025 | -8,170.12% |
| Sep 30, 2025 | -4,318.14% |
| Jun 30, 2025 | -6,732.55% |
| Mar 31, 2025 | -1,806.73% |
| Dec 31, 2024 | 3,198.55% |
| Sep 30, 2024 | -3,876.49% |
| Jun 30, 2024 | 44.71% |
| Mar 31, 2024 | -208.63% |
| Dec 31, 2023 | -2,379.12% |
| Sep 30, 2023 | -137.41% |
| Jun 30, 2023 | -342.85% |
| Mar 31, 2023 | -322.97% |
| Dec 31, 2022 | 33.37% |
| Sep 30, 2022 | -39.66% |
| Jun 30, 2022 | 34.00% |
| Mar 31, 2022 | 29.65% |
| Dec 31, 2021 | 41.34% |
| Sep 30, 2021 | -8.46% |
| Jun 30, 2021 | -1.31% |